• AI System For Diagnosing Rare Diseases and Solving Medical Cold Cases

    May 23 | Diagnostics World | Using an artificial intelligence (AI) model that was trained on millions of variants from identified genetic disorders and incorporates the complex decision-making process of human molecular scientists, investigators at Baylor College of Medicine are on track to automate the diagnosis of an enormous number of undiagnosed conditions. More
  • Clinical Trial Underway for New-and-Improved Prostate Cancer Test

    May 21 | Diagnostics World | Researchers at the University of Michigan (U-M) have developed a urine test for prostate cancer known as MyProstateScore 2.0 (MPS2), now a property of spinoff LynxDx, which they expect to significantly improve upon the performance of existing assays by focusing on clinically significant cancers and capturing more biomarkers in a single test. More
  • 3D Printing Could Make Mass Spectrometry Local

    May 16 | Diagnostics World | Science and technology have moved up the appearance of a high-performance point-of-care mass spectrometer to a near-term possibility, which would make it both cheaper and more convenient to monitor chronic health conditions from just about anywhere a 3D printer could be deployed—including the jungle, Antarctica, and future colonies on Mars. More
  • Liquid Biopsy Under Development for Measuring Drug Response

    May 15 | Diagnostics World | The lab of W. Andy Tao, professor of biochemistry at Purdue University, is pioneering a way to assess drug response based on metabolizing proteins found in circulating extracellular vesicles (EVs), which could serve as a surrogate of their expression level in the liver and become therapeutic targets for some cancers. More
  • Functional Precision Medicine Shows Promise for Kids With Tough Cancers

    May 14 | Diagnostics World | A cancer researcher at Florida International University (FIU) has developed a functional precision medicine (FPM) approach to oncology treatment decision-making that combines genomic profiling with drug sensitivity testing on patient-derived tumor cells. Children with relapsed or refractory cancers are among the initial beneficiaries. More
  • The Cost of Overtreatment: How Improved Cancer Diagnostics Can Help Preserve Key Healthcare Resources

    May 10 | Diagnostics World | Every resource in healthcare is precious. The last few years have tested healthcare systems in almost every way, with significant impacts on their long-term financial health and, by extension, the quality of care they can provide. A 2023 report by the American Hospital Association estimates that overall hospital expenses rose by 17.5% between 2019 and 2022. More
  • Thermo Fisher on the Rise of Next-Generation Sequencing CDx

    May 07 | Diagnostics World | In oncology, it is well appreciated that time is life. Diagnostics are therefore valuable not just to determine the disease state of patients but how best to treat them, says Jane Li, senior director of oncology, pharma, and CRO partnerships related to clinical sequencing at Thermo Fisher Scientific. More
  • Unpacking the New FDA LDT Rule

    May 02 | Diagnostics World | A much-anticipated rule to regulate laboratory developed tests (LDTs) as medical devices has arrived, with significant implications for the diagnostic industry and patient care. Here’s a closer look at the historical context underlying the new rule, the debate leading up to this moment, recent updates, and the road ahead. More
  • New Test Looks at Unique Response of MS Patients to Epstein-Barr Virus

    May 01 | Diagnostics World | Significant evidence now exists implicating the Epstein-Barr virus (EBV) as a causal factor in the development of multiple sclerosis (MS), making treatment of the virus a priority. To that end, research scientists at Trinity College Dublin have developed a blood test to measure the immune response to EBV that could be used as an outcome measure in future clinical trials in people with established MS. More
  • Digital Twin of Infant Microbiome Reliably Predicts Cognitive Deficits

    Apr 30 | Diagnostics World | Researchers at the University of Chicago have succeeded in creating a digital twin of the gut microbiome of premature infants that reliably models the many interactions taking place between quickly changing bacterial inhabitants. The so-called “Q-net” model, created with generative artificial intelligence (AI), was used to make predictions about which infants were going to have neurodevelopmental deficits using head circumference as the proxy. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more